PHIOGEN

Phiogen is a pre-clinical stage biotechnology company dedicated to developing next-generation bacteriophage therapeutics to address the global threat of antimicrobial resistance. Spun out of Baylor College of Medicine's TAILOR Labs, the company leverages a proprietary platform that utilizes directed evolution and high-throughput screening to create "dual-action" phage products. These therapies are engineered to provide immediate bactericidal activity while simultaneously stimulating the host's immune system to prevent infection recurrence. Phiogen's lead programs focus on recurrent urinary tract infections (rUTI) and extraintestinal pathogenic E. coli (ExPEC) bloodstream infections, with additional research targeting other high-priority pathogens. The company aims to shift the treatment paradigm from repeated antibiotic use toward durable bacterial eradication and long-term immune protection.